Why the study?
Whether PCATMA has value on an individual patient basis remains to be determined, and technical and clinical factors complicate clinical implementation, requiring a standardized methodology.
Design
Review
Authors
Loading...
Supports PCATMA as a CT biomarker for coronary inflammation; leaves open standardization and prospective validation before clinical use.
PCATMA derived from CT images is a promising non-invasive imaging biomarker for evaluating coronary inflammation and identifying high-risk plaques, though standardized measurement methodologies are required before widespread clinical implementation.
Ma et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: